Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Expenses (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Operating Expenses data on record, last reported at $67.6 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 12.37% year-over-year to $67.6 million; the TTM value through Dec 2025 reached $283.6 million, up 36.72%, while the annual FY2025 figure was $283.6 million, 36.72% up from the prior year.
  • Operating Expenses reached $67.6 million in Q4 2025 per COLL's latest filing, up from $67.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $75.6 million in Q1 2025 and bottomed at $32.0 million in Q3 2021.
  • Average Operating Expenses over 5 years is $48.0 million, with a median of $41.6 million recorded in 2022.
  • The widest YoY moves for Operating Expenses: up 82.68% in 2024, down 20.45% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $32.8 million in 2021, then rose by 15.99% to $38.0 million in 2022, then dropped by 13.38% to $32.9 million in 2023, then surged by 82.68% to $60.2 million in 2024, then increased by 12.37% to $67.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $67.6 million in Q4 2025, $67.1 million in Q3 2025, and $73.3 million in Q2 2025.